EZH2 and plasma cell myeloma: In support of this notion, the combination of EZH2 and BMI-1 (PRC1) inhibitors have synergistic anti-myeloma activity using HMCLs and CD138+ myeloma cells isolated from newly diagnosed or relapsed MM patients [124].